Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma
Aparna Jayachandran(The University of Melbourne), Andreas Behren(The University of Melbourne), Jonathan Cebon(La Trobe University), Sonja J. McKeown(Discovery Institute), Colin R. Goding(Ludwig Cancer Research), Pu‐Han Lo(Ludwig Cancer Research), Matthew Anaka(Ludwig Cancer Research), Christopher Hudson(Ludwig Cancer Research), Prashanth Prithviraj(The University of Melbourne), Laura J. Vella(The Royal Melbourne Hospital)
Cited by 143
Related Papers
Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
|Journal of Clinical Oncology|2000|1.3k
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
|Proceedings of the National Academy of Sciences|2004|440
A rigorous method to enrich for exosomes from brain tissue
|Journal of Extracellular Vesicles|2017|327
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial
|The Lancet Oncology|2017|247
Macrophage Migration Inhibitory Factor Induces Macrophage Recruitment via CC Chemokine Ligand 2
|The Journal of Immunology|2006|229